Log in

NASDAQ:VRNAVERONA PHARMA P/S Stock Price, Forecast & News

$4.76
-0.01 (-0.21 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$4.40
Now: $4.76
$4.89
50-Day Range
$3.75
MA: $4.41
$6.12
52-Week Range
$2.01
Now: $4.76
$12.89
Volume40,386 shs
Average Volume53,522 shs
Market Capitalization$62.69 million
P/E RatioN/A
Dividend YieldN/A
Beta0.04
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and II clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, chronic asthma, and allergic rhinitis. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.
Read More
VERONA PHARMA P/S logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.60 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VRNA
CUSIPN/A
Phone44-20-3283-4200

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.51 per share

Profitability

Net Income$-40,780,000.00

Miscellaneous

Employees22
Market Cap$62.69 million
Next Earnings Date8/4/2020 (Estimated)
OptionableNot Optionable

Receive VRNA News and Ratings via Email

Sign-up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter.

VERONA PHARMA P/S (NASDAQ:VRNA) Frequently Asked Questions

How has VERONA PHARMA P/S's stock been impacted by COVID-19 (Coronavirus)?

VERONA PHARMA P/S's stock was trading at $4.84 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, VRNA stock has decreased by 1.7% and is now trading at $4.76. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of VERONA PHARMA P/S?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VERONA PHARMA P/S in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for VERONA PHARMA P/S.

When is VERONA PHARMA P/S's next earnings date?

VERONA PHARMA P/S is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for VERONA PHARMA P/S.

What price target have analysts set for VRNA?

2 analysts have issued 1 year price targets for VERONA PHARMA P/S's shares. Their forecasts range from $34.00 to $50.00. On average, they expect VERONA PHARMA P/S's stock price to reach $42.00 in the next year. This suggests a possible upside of 782.4% from the stock's current price. View analysts' price targets for VERONA PHARMA P/S.

Has VERONA PHARMA P/S been receiving favorable news coverage?

News coverage about VRNA stock has been trending very negative recently, InfoTrie reports. The research firm scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. VERONA PHARMA P/S earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near term. View the latest news aboutVERONA PHARMA P/S.

Are investors shorting VERONA PHARMA P/S?

VERONA PHARMA P/S saw a increase in short interest in May. As of May 15th, there was short interest totaling 14,800 shares, an increase of 78.3% from the April 30th total of 8,300 shares. Based on an average daily volume of 59,200 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.2% of the company's stock are short sold. View VERONA PHARMA P/S's Current Options Chain.

Who are some of VERONA PHARMA P/S's key competitors?

What other stocks do shareholders of VERONA PHARMA P/S own?

Who are VERONA PHARMA P/S's key executives?

VERONA PHARMA P/S's management team includes the following people:
  • Dr. Jan-Anders Karlsson, CEO & Exec. Director (Age 64)
  • Mr. Piers John Morgan, Chief Financial Officer (Age 53)
  • Ms. Claire Louise Poll L.C.S.W., B.A., B Juris, LLB, ASIA, Gen. Counsel (Age 52)
  • Ms. Victoria Stewart, Director of Communications
  • Dr. Peter Spargo, Sr. VP of Chemistry Manufacturing & Controls (Age 57)

When did VERONA PHARMA P/S IPO?

(VRNA) raised $61 million in an initial public offering on Thursday, April 27th 2017. The company issued 4,500,000 shares at a price of $13.49 per share. Jefferies and Stifel served as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers.

What is VERONA PHARMA P/S's stock symbol?

VERONA PHARMA P/S trades on the NASDAQ under the ticker symbol "VRNA."

Who are VERONA PHARMA P/S's major shareholders?

VERONA PHARMA P/S's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vivo Capital LLC (11.34%), venBio Partners LLC (3.47%), Tekla Capital Management LLC (1.92%), D.A. Davidson & CO. (0.66%), Wedbush Securities Inc. (0.54%) and Clear Creek Financial Management LLC (0.28%).

Which major investors are selling VERONA PHARMA P/S stock?

VRNA stock was sold by a variety of institutional investors in the last quarter, including venBio Partners LLC, Tekla Capital Management LLC, and Wedbush Securities Inc..

Which major investors are buying VERONA PHARMA P/S stock?

VRNA stock was bought by a variety of institutional investors in the last quarter, including Vivo Capital LLC, D.A. Davidson & CO., and Clear Creek Financial Management LLC.

How do I buy shares of VERONA PHARMA P/S?

Shares of VRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is VERONA PHARMA P/S's stock price today?

One share of VRNA stock can currently be purchased for approximately $4.76.

How big of a company is VERONA PHARMA P/S?

VERONA PHARMA P/S has a market capitalization of $62.69 million. The company earns $-40,780,000.00 in net income (profit) each year or ($3.10) on an earnings per share basis. VERONA PHARMA P/S employs 22 workers across the globe.

What is VERONA PHARMA P/S's official website?

The official website for VERONA PHARMA P/S is www.veronapharma.com.

How can I contact VERONA PHARMA P/S?

VERONA PHARMA P/S's mailing address is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. The company can be reached via phone at 44-20-3283-4200 or via email at [email protected]

This page was last updated on 5/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.